DRUG DISCOVERY 2023:
DIVERSE THINKING- NEW PERSPECTIVES


POSTERS

POSTERS AT DRUG DISCOVERY 2023

Thank you to everyone who submitted a poster, we've an astonishing 200+ posters submitted.  Please see below to find out more.

Poster Number Poster title First Name Last Name Vendor ECP
1 Designing and developing NRP1 inhibitors for Alzheimer's  HADEEL ABOZENADAH No Yes
2 DragonFold: A Deep Learning Protein-Ligand Co-Folding Platform Peter Canning No No
3 Harnessing and Validating Deep Learning-based Image Analysis for Cell Painting as an Unbiased Approach to Phenotypic Drug Discovery David Egan No No
4 Rapid cell-free expression and purification screen through digital microfluidics on eProtein DiscoveryTM Suzanne Fuld Yes No
5 Age related DNA methylation in healthy and disease states Sheraz Gul No No
6 Using AI to understand and optimise away from toxicity Jordan Lane No No
7 Biomed News – a free machine learning based platform to help discover and share new biomedical research literature Gavin McStay No No
8 Accelerating BRPF1b hit identification with BioPhysical and Active Learning Screening (BioPALS)   Zandile Nare No Yes
9 A database of Causal AI-identified genes and gene clusters to accelerate the discovery of targets, combination therapy, and indication extension in cancer: ALaSCAdb Raminderpal Singh No No
10 AI applications in mechanistic mathematical modelling for health and life sciences Piotr Słowiński No No
11 Biomarker and Druggable Target Discovery via Systematic Deep Mining and Pathway Reconstruction Dimitrios Zafeiris No Yes
12 Nanoemulsion as a Novel Nanocarrier for Topical Delivery of Mupirocin Bahjat Alhasso No Yes
13 Antibody Discovery Using the Galaxy® Library Platform Tina Baluta No Yes
14 Brain permeable AMP-activated protein kinase (AMPK) activator R481 amplifies hypoglycaemia counterregulation in healthy rats without worsening hyperglycaemia in diabetic rats. Craig Beall No No
15 Integrated Fragment-Based Drug Discovery (FBDD) services at Selvita Aleksandra Bebel Yes No
16 Antibody Validation and Antigen Discovery by combining Protein and Peptide Microarrays Marc Botcherby No No
17 Bringing in vivo tests much earlier in the drug discovery process using the nematode C. elegans Guillermo Calvo Navarrete No Yes
18 A Platform for Novel Target Discovery - Delivering Complexity & Robustness into Arrayed Immuno-Oncology Screens at AstraZeneca Will Chiang No No
19 LifeArc Effector Function 'Toolbox' Catherine Christabel No Yes
20 A novel mechanism of action of Acid Ceramidase inhibition by Tamoxifen Mari Davies No Yes
21 Effects of berberine chloride on uterine motility evoked by viral mimetic poly I:C James Downing No No
22 Biopharmaceutical discovery Claudia Driscoll No Yes
23 Development of Optimum Inhalable EGCG nano-Liposome as a Potential Therapy for Pulmonary Arterial Hypertension using Box-Behnken Design Fatma Haddad No Yes
24 Navigating the Ophthalmic Frontier: Preclinical Models for Targeted Therapies Kevin Harkin No Yes
25 Long-term experience of using Anti-IL-12/23 p40 IgG as a reference therapeutic in adoptive T cell transfer models of colitis Amy Horwell No No
26 Protein-drug interactions measured with high throughput 2D-IR spectroscopy Neil Hunt No No
27 Integrated Fragment-Based Drug Discovery (FBDD) services at Selvita Alexander Ignatyev Yes Yes
28 Design optimal drugs - Unravel biological mechanisms by looking at single molecules in real-time.   Artur Kaczmarczyk Yes Yes
29 Specific Extracellular Vesicle detection and isolation in complex samples using FO-SPR Susanna Lovell Yes No
30 Harnessing the Power of Limited Proteolysis and High-Resolution Mass Spectrometry Proteomics for Target Deconvolution of Small Molecule Drug Candidates  Nancy Malintan Yes No
31 Mammalian Display for Antibody Discovery Sara Mcdowell Yes Yes
32 Developing Multiscale models to study molecular transport into tissues Melissa Mitchell No Yes
33 An in vitro screening cascade for the identification of novel KCNK13 inhibitors Emily Moverley-Foster No Yes
34 Identification of new promising GPR120 agonists to tackle central and peripheral disorders Federico Munafò Yes Yes
35 “TSA meets HTS to discover and characterize novel protein binders with inhibitory activity targeting pepsin-like proteases” Simone Nenci Yes No
36 Fabrication of Antibacterial NO Releasing Cellulose Acetate Nanofibers for Wound Healing Applications. Cadhan O'Garra No Yes
37 Comparison of Sequence Diversification Methods for Accelerated Antibody Optimisation Larissa Ouro No Yes
38 Increasing DNA Encoded Library Screening Resolution Using HT-SPR Jonathan Popplewell Yes No
39 Development of a High-Throughput Turbidity Assay to Determine Compound Solubility in Bioassays Sara Rix-Perez No Yes
40 Genetic support for FDA-approved medicines over the last decade Polina Rusina No Yes
41 CONSTRUCTION OF DUAL EXPRESSION VECTORS AND STRAINS FOR BIOSYNTHESIS OF MULTIMETHYLATED MOLECULES IN MICROBIAL HOST CELLS. Umesh Prasad Sah hathi No Yes
42 Effects of Miquelianin from Calystegia silvatica on the TGF-b1 signaling pathways in Pulmonary Arterial Hypertension (PAH) Sila Ozlem Sener No Yes
43 Screening Environmental Microbes for Antimicrobials and Natural Products Priyanka Sharma No Yes
44 Evaluation of drug target engagement on pharmacodynamic biomarkers in human plucked scalp hair Greg Tudor No No
45 HTP detergent screening for membrane protein solubilisation using nanolitres of sample Joanne Walter Yes No
46 Binding kinetics on live cells to unravel how epitope binding influences antibody dependent complement engagement for therapy of B-cell malignancies  Hadis Westin Yes No
47 Pharmacological activation of long-form PDE4 enzymes suppresses cystic disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease Claire Whitworth No No
48 Aged beagle dogs as a clinically relevant model of Alzheimer’s Disease Róisín Winters No Yes
49 A high throughput mitochondrial functional assay for screening and optimisation of potent cyclophilin D inhibitors to fight acute illnesses Muhammad Awais No No
50 Application of 3D organoid assays for drug screening and compound optimization Benjamin Bader Yes No
51 High throughput characterization of advanced 3D liver models for in vitro hepatotoxicity studies Rachel Bleach Yes Yes
52 Chemogenomic screening of the NLRP1 pathway Isobel Blower Yes Yes
53 Autism & Epilepsy Disease modelling for drug discovery using patient-derived neuronal co-cultures Camilla Bosone No Yes
54 Biotinylation of recombinant proteins by co-expression with BirA in a range of different cell hosts Emma Cains Yes No
55 Enhanced Panc1 cancer cell killing by combined gemcitabine and binary weapon treatment though activation of Wnt5a pathway Yu-Shan Chen No Yes
56 Development of a Novel Milli-fluidic Liver Tissue Platform for Mechanistic Drug-Induced Liver Injury (DILI) studies Murat Cirit Yes No







57 StarBright Dyes and the ZE5 Cell Analyzer: Generating Fast, Reproducible, High Resolution Flow Cytometry Data Richard Cuthbert Yes No
58 Enhancing transcriptome analysis using GeneGini Philip Day No No
59 High Content Screening in 3D models including the tumoral Extracellular Matrix Veronique De Conto Yes Yes
60 Investigating lysosomal membrane proteins using SSM-based electrophysiology: Improving amplification and accessibility Giovanna De Filippi Yes No
61 NanoBiT biosensors to investigate FFA4 signalling in adipocyte spheroids Elaine Duncan No Yes
62 How to tackle difficult targets in CETSA Navigate Helen Ericson Vallhov Yes No
63 Adoption and validation of an automated phenotypic profiling workflow based on the JUMP Cell Painting assay. Marie Fisher Yes No
64 From clonogenic to 384-well: miniaturisation and automation enables rapid hit validation from whole-genome CRISPR screens Millie Fox No Yes
65 ToxReady™ Assay Ready Plates: Removing Cell Culture from Drug Screening Natalia Gonzalez Martinez Yes Yes
66 Evaluation of protein biomarkers in brain homogenate and plasma from different animal models of Alzheimer's Disease: P301S and APP/PSEN1 Philemon Gyasi-Antwi Yes Yes
67 Research at the Living Systems Institute Exeter Nicholas Harmer No No
68 Identify the importance residues on the binding pocket of Cannabinoid 1 receptor  Pattarin Hompluem No Yes
69 Developing Novel NanoBRET™ Target Engagement Assays Using NanoBRET™ 590 Dyes Amber Insch Yes No
70 CETSA Navigate HT: Concepts and considerations in assay development Merve Kacal Yes Yes
71 Development of microscopy tools to inform drug discovery Rebecca Kelly No No
72 Comparison of cellular target engagement methodologies for the identification of ULK1 interacting small molecules Freja Khela No Yes
73 CRISPR Prime editing for drug discovery MiYoung Lee No No
74 Development of a comprehensive high-throughput cell analysis system for cancer drug discovery Bettina Lickiss Yes No
75 Implementing rapid quality assessments in the up-stream process for maintaining high-quality iPSC cultures. Rosa Loffredo Yes No
76 Grow your own brain cells: neuronal differentiation as a tool for therapeutic development Tom Miller Yes Yes
77 Human intestinal organoid culture system for drug-induced gastrointestinal toxicity screening  Claire Minguez Yes

78 Flow Cytometry: Immunophenotyping and cell subsetting using fresh healthy donor whole blood samples Lucy Minkley Yes Yes
79 Bladder Cancer organoids biobank as a platform for drug response and sensivity  Mahsa Mollapour Sisakht No Yes
80 Applying droplet fluidics to mycobacterial drug discovery.  Antonia Molloy No Yes
81 Coupling DRUG-seq transcriptomics with arrayed CRISPR screening to identify mechanistic insights and drivers of resistance to clinical therapies in ER+ breast cancer.  Lambert Montava Garriga No Yes
82 Organoid co-cultures with autologous T cells to assess toxicity and efficacy of bispecific antibodies Daniele Mori Yes Yes
83 PRCISR™ CRISPR: PCR-free Libraries, Screening Services Micheal Murphy Yes No
84 Establishing assays to investigate  combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses. Wen Hao Neo Yes Yes
85 A genome-scale CRISPR knockout screen to study synthetic lethal interactions of PARP inhibitors Christoph Neumayr Yes No
86 Fully automated workflow and best practice considerations for effective high throughput automated patch clamp recordings of cardiac ion channels Alison Obergrussberger Yes No
87 Large scale generation of human iPSC-derived sensory neurons for CIPN and pain research  Amr Othman Yes Yes
88 iPSCs as a model for Neuroinflammation Alicia Overall Yes Yes
89 Increasing Accessibility to Organoid Models for Drug Discovery Monica Patel No Yes
90 USING LABEL FREE TECHNOLOGIES TO CHARACTERISE THE PHARMACOLOGY OF THE MAS RELATED GPCR FAMILY MEMBER D (MRGPRD) RECEPTOR Cheryl Pattie No No














91 Early-stage drug discovery of Novel LIMK1 inhibitors for the treatment of Fragile X Syndrome and Acute Myeloid Leukaemia  Josephine Pedder no No
92 CETSA HT : Accelerating drug discovery for complex targets  Nisha Peter no No
93 Untargeted Metabolomics by OrbiSIMS and LC-MS/MS Reveals Metabolic Changes Linked to Azithromycin in Escherichia coli FATIMAH QASSADI no Yes
94 Lipidomic profiling reveals altered lipid metabolism in primary progressive MS patients from phenotypically normal white matter and control biopsies Samrina Rehman no No
95 Development of an optimised and cost-effective workflow for deriving clonal iPSC lines Claire Richards Yes No
96 High content image analysis of human cortical adherent organoids: 3D MICro-brains Maria Roa Oyaga Yes No
97 An integrated approach for early in vitro seizure prediction utilising human derived induced pluripotent stem cells and human ion channel assays Kimberly Rockley Yes Yes
98 Driving Discoveries with Curated Single-Cell Data in Immunology Natalie Russi Yes No
99 Characterisation of the monocyte-like THP-1 cell line response to hypoxia in vitro. Lucy Sayer No Yes
100 Revealing in-vitro functionality of arrayed CRISPR KO edited T cell lymphocytes. Antonio Serrano Yes No
101 3D tumour and tumour-immune microenvironment cell culture models in animal-free nanofibrillar cellulose hydrogels. Jonathan Sheard Yes No
102 Shedding light on the MoA of degraders Carola Sparn Yes Yes
103 Top Strategies for Optimizing 3D Cell Culture: From Essential Attributes to Improved Reproducibility Emma Storr Yes No
104 Primary cell in vitro platforms for pre-clinical anti-inflammatory drug discovery research Martin Sutton No Yes
105 Neural Mechanism associated with Deletion and Duplication Syndrome  Yasir Ahmed Syed No Yes
106 High-throughput Phenotypic Screening to Identify Stimulators of Autophagy and Drugs for the Treatment of Parkinson’s Disease James Taylor YEs No
107 Molecular Technologies to Aid Target Validation & Lead Compound Evaluation  Alex Timmis Yes Yes
108 Assay Ready Cryopreservation of Hepatocytes as 2-D Monolayers Ruben Tomas Yes Yes
109 The secret to living forever: Exploring cellular aging. Paige Tongue Yes Yes
110 The use of intestinal organoids as a preclinical screen to assess gastrointestinal (GI) toxicity and barrier integrity. Valentina Ubertini No Yes
111 Organoid monolayers: a patient-relevant platform to study intestinal barrier function, inflammatory bowel disease (IBD) and GI toxicity. Eider Valle-Encinas Yes Yes
112 Our Drug Discovery Capabilities Emily Wallace No Yes
113 High-order multiplexing of image based cell assays with the SemaPlex platform Daniel Weekes Yes No
114 Pharmacological Characterisation of Human, Rat, Dog and Pig Melanocortin 2 Receptors Rose Wilcox No Yes
115 Development of a patch clamp assay to characterise native endo-lysosomal ion channels.  Adam Young Yes Yes
116 Synthetic Mimics of Nature - Native Membrane Signal Presentation Platform for T Cell Activation & Expansion Joel Yu Yes No
117 High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry Sun Yung Yes No
118 Recipharm OT Chemistry and Oncopeptides: Successful Collaboration in the Development of Melflufen, a Peptidase-Potentiated Alkylating Agent for the Treatment of Multiple Myeloma Fana Abraha No No
119 Ethylacetate Extract of Chlorophytum alismifolium improves Serum Insulin Levels and Pancreatic Histomorphology in Hyperglycaaemic Rats Abdulhakim Abubakar No Yes
120 Cell-Permeable Cyclic Peptide Library Generation for Target-Based Screening Siddique Amin No Yes
121 APPROACH TO RATIONAL IDENTIFICATION OF LEAD MOLECULAR GLUE DEGRADERS FOR CASEIN KINASE 1α George Buckley No No
122 Evaluation of retinoic acid receptor dual acting modulator NVG645 for ALS and AD  in vitro. Paul Chazot No No
123 DEMONSTRATING AN EASE-OF-USE BENCHTOP TIME OF FLIGHT DETECTOR AS AN EASE-OF-USE SOLUTION FOR ACCURATE MASS MEASUREMENTS IN FORCED DEGRADATION STUDIES Chris Henry Yes No
124 A Phenotypic Screen of Novel Compounds for the Treatment of Parkinson's Disease Louise Heywood No Yes
125 The degradation of pathogenic protein aggregates Lois Lewis No Yes
126 Novel Boronic Acids for Combating Anti-Microbial Resistance in P.aeruginosa Arshnous Marandi No Yes







127 High-Throughput Kinetic Characterisation of USP30 Inhibitors Showing Different Modalities Emma Murphy No No
128 Chemical Space Docking: Mining Billion-Sized Compound Collections for ROCK1 and PKA Inhibitors Alexander Neumann No Yes
129 Structure-based design of small macrocyclic CDK9 degraders as chemical biology tools and beyond Keith Payne Yes No
130 Fine-Grained Binding Pocket Exploration Through Ligand Mutation and Fragment Growing Filomena Perri No Yes
131 Medicinal Chemistry of Uridyl Peptide Antibiotics: Genochemetic & Synthetic strategies for analogue generation. Sunil Sharma No No







132 Why integrated drug discovery? Kirsty Winn Yes No
133 Development and Biological Evaluation of Novel α-Helix Mimetic  Prodrugs as Leads for Prostate Cancer Treatment Natalia Swiatek No Yes
134 Engineering Bicyclic Small Molecule Heterocycles as Anti-malarial Therapeutics: Design, Synthesis and Biological Studies Joaquim Figueiredo No No
135 [14C]-Radiosynthesis of Remetinostat (SHP-141) Niall Hamilton No No
136 Pragmatic Process Development J. Mikael Hillgren No No
137 Utilizing a compact  Time of Flight Mass Spectrometer(TOF) for rapid accurate mass information in a walk-up environment. Mike Jones Yes No
138 Industrial drug design using cryo-EM Ferdinand Krupp No Yes
139 Degradation of Integral Membrane Proteins with PROteolysis TArgeting Chimeras (PROTACs): a challenge we can win? Camilla Ruffilli No Yes
140 (Radio)Isotope labelling at Almac for Clinical Studies Rajkumar Sundaram No Yes
141 Contract Research BAJRANG WAGHMARE Yes No
142 Patient in the lab®: downscaling patient-derived organoid screening Yasmine Abouleila Yes Yes
143 A multi-parametric screening for the identification of naturally occurring compounds with anti-aging properties  Chiara Annunziata No Yes
144 Identification of Antagonists Through Development and Validation of a Gq Coupled Purinergic Receptor Signalling Assay  Emma Armstrong No No
145 Identification of metal complexes with broad-spectrum antibacterial activity  Emily Baker No Yes
146 Targeting Notch: a potential synthetic lethal cancer treatment Bethany Barnes No Yes
147 The Sygnature CHARMED Platform - Combinatorial High-throughput Assembly and Review of Molecular Degraders Hanae Benelkebir Yes No
148 Single molecule real-time analysis of dynamic nucleic acid interactions Christine Blancher No No







149 CRISPR screening in iPSC-derived microglia for drug target discovery and validation Ann Byrne Yes No
150 High Content Phenotypic Screening of Cell Paint Assays on Araceli Endeavor Paul Carman Yes No
151 A UK Academic DNA-Encoded Library Screening Resource Sergi Celis No Yes
152 Developing a plate-based LC/MS assay to quantify m6A as part of a screening cascade for METTL3 inhibitors Oliver Chan Yes Yes
153 ‘Development of a HTRF Assay for the Characterization and MoA Assessment of DHPS/eIF5A Tool Compounds Jonathan Clark No No
154 DNA-Encoded Library Screening of DNA Binding Proteins  Catriona Corbishley No Yes
155 RxNfinity: A novel structure based hierarchical synthon docking approach for the rapid dentification of small molecule modulators. João Victor De Souza Cunha No No
156 The PAINful experience to identify USP8 inhibitors for Parkinson’s Disease. Parul Dixit No Yes







157 High-throughput Screening of Formulations & Process Conditions for LNP Synthesis Alison Dowsett No No







158 Zebrafish models for drug discovery and screening Helen Eachus No Yes
159 Development of non-covalent inhibitors of acid ceramidase to treat lysosomal storage disorders Gabrielle Evans No Yes







160 FRET association binding kinetics for accurate probe characterisation Sarah Folliet No Yes
161 A high-throughput screen to identify novel therapies to treat diseases of aging Sian Gardiner No Yes
162 High-throughput affinity selection mass spec assay to discover small molecule ligands for cell surface receptors Zachary Gurard-levin Yes No
163 Measuring protein ligand binding with an endogenous HiBiT CETSA test system Duncan Hall Yes No
164 Combinatorial Indexing For Single Cell Sequencing With CRISPR Amy Hamilton Yes No
165 Giving HTS Library Plates a New Lease of Life Through the Use of a DMSO Rich Atmosphere Fraser Hughes No No
166 anthony.huxley@liverpoolchirochem.com Tony Huxley No No
167 Kinetic screening using Grating-Coupled Interferometry (GCI) – highly sensitive biosensor-based assays enable the identification of weak fragment hits across a diverse set of challenging targets Marta Janczuk-Richter Yes Yes
168 Combination of Affinity Selection Mass Spectrometry with Biophysical approaches to identify and characterize biomolecules binders Helene Jousset Sabroux Yes No
169 Fragment screening using the Biacore 8K+ platform and an evaluation of the AI driven Intelligent Analysis software. David Kallenberg No Yes
170 Identification of novel autoantibody signatures related to non-motor symptoms in individuals with high-risk of Parkinson’s Disease, using KREX-based functional protein microarrays. A cross-sectional study. Elwira Kaminska No No
171 Integration of Bead-Assisted Ligand Isolation Mass Spectrometry (BALI-MS) for Enhanced Hit Validation in DNA Encoded-Library Screening Campaigns Vasudev Kantae No Yes
172 Opportunities and Challenges of Complex Cell-Based Assays for High Throughput Screening  Johanna Kastl No No
173 Development of phosphatase activity assay for high-throughput compound library screening of SHIP1 Emma Kennedy No Yes
174 The potential of biophysical techniques in advancing drug discovery programs Jeff Kennedy No No
175 High-throughput Screening of Formulations & Process Conditions for LNP Synthesis Alex Kerr Yes No
176 DEL Screening of Multimeric Proteins in Living Cells Leif Kongskov Larsen No No
177 Expanding the E3 ligase repertoire for Targeted Protein Degradation  Roxanne Lau No No
178 Advancing Membrane Protein Analysis with Polymer Lipid Particle (PoLiPa) technology for Enhanced Drug Discovery William Lee Yes No
179 Utilising Affinity Selection Mass Spectrometry (ASMS) to rapidly identify competitive binders to novel binding site on oncology target Poppy Llowarch No Yes
180 HTS-screening Technology Platform: Helicases Inhibitors Restuan Lubis No Yes
181 FOSTERING DRUG DISCOVERY THROUGH THE DEVELOPMENT OF HIGH-PERFORMANCE INNOVATIVE PROBES  Maria Majellaro Yes Yes
182 Arrayed CRISPR KO screen in primary immune cells for the identification of novel targets for the treatment of systemic lupus erythematosus Chris Oliphant No No
183 High content imaging is now high throughput: End to end high content imaging and subcellular analysis of autophagy in minutes  Cristina Ortiz-mateos Yes Yes
184 Genome-wide pooled CRISPR screening in primary T cells at the FGC Angelos Papadopoulos No No
185 Recombinant production of Ras proteins for fragment-based drug discovery Camila Pasquali No Yes
186 Title: Application of HiBiT Internalisation Assays in GPCR Drug Discovery for Colorectal Cancer Martin Pearce Yes Yes
187 Assessing ligand-induced stabilisation of a soluble protein using ThermoBRET Themiya Perera No Yes
188 From Virtual to Reality: Representing Ultra-Large Virtual Libraries Through a Diverse (Physical) Sub-Set for HTS Ilaria Proietti Silvestri No No
189 PROTAC platform: Enabling rapid design, characterisation and assessment Philip Rawlins Yes No







190 What is Happening in High Throughput Screening at Sygnature Discovery? James Reekes Yes Yes







191 Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine   2,3-dioxygenase 1 (IDO1) using virtual screening Johannes Reynisson No No
192 HiBiT Split Reporter Target Engagement Assay Development Thomas Ryan Yes Yes
193 Characterising the Irreversible: Using Biophysics to Enable Covalent Drug Discovery Joud Sabouni Yes Yes
194 Comparison of Single Live Cell Sampling Methods for Lipidomics Mailyn Schuermann Yes

195 Harnessing the Biophysical Fragment Screening Sweet Spot to Discover New Chemotypes for BRPF1b Inhibition Andrew Scott No No







196 Live cell, kinetic monitoring enables study of  complex formation and target ubiquitination  induced by proteolysis targeting chimeras manoja Sivakumar Yes No
197 Power Your Early-Stage Drug Discovery Projects: Innovation in Assays, High-Throughput Screening, Hit-to-Lead and Beyond Rebecca Steele Yes

198 ASMS Deployment to Broaden High Throughput Hit Finding Capabilities at Sygnature Discovery Alexandra Stowell Yes No
199 Proteins & Structures: High-quality recombinant proteins and structural biology services Anna Suchy Yes No
200 Implementing Plate Reformatting to Optimise SMG-HTS Efficiencies Finn Sullivan No Yes
201 Kinetic profiling of cannabinoids at CB1 and CB2 receptors using a TR-FRET-based binding assay David Sykes No Yes
202 GPCR hit confirmation using a thermostability readout  ThermoBRET Parisa Tavakoli No Yes
203 Identification of HTL-927 as a small molecule C3aR antagonist  Emma Tripp No Yes
204 Cas13: A Safer and Precise Frontier in Drug Discovery and Therapeutic RNA-Editing sunay Usluer No Yes
205 Novel Genome-Wide CRISPR Screening method uses nuclear localisation and nuclei sorting to Identify Regulators of Hepatic Insulin Signalling  Anna Veprik No Yes
206 A novel membrane-based Gi-CASE biosensor assay for profiling compounds at cannabinoid receptors Dmitry Veprintsev No No
207 MDC Chemical Protein Stability Assay (CPSA) - A Novel Target Engagement Approach John Vincent No No
208 Robust automated- and interactive protocols for NMR-based fragment drug discovery and design (FBDD) using the CcpNmr AnalysisScreen programme Geerten Vuister No No
209 An end-to-end CRISPR screening pipeline to identify synthetic lethal partners of ARID1A and validate novel target opportunities in cancer Simon Vyse No No
210 RxCelerate: Architects of Drug Discovery and Development Amy Warner No No
211 Establishing a screening cascade to identify inhibitors of the nicotinic acetylcholine receptor α6 subunit (nAChRα6) Rosie Waters No No
212 Cell Painting in Pictures and Numbers: An Integrated Image and Data Analytics Platform for Accelerating Drug Discovery.   Victor Wong Yes No
213 Monitoring microbial diversity in healthy volunteers using 16S Metagenomic sequencing James McConnell No Yes
214 Development of high throughput RT-qPCR assay to assess small molecule targeting RNA via exon skippers Giulia Bonetto No Yes
215 Bolster the reproducibility of your 3D cellular aggregates assay with automated spheroids and organoids selection and isolation Sébastien Clerc Yes No
216 Automating Thermal Shift Assays: CETSA Melt Curves Matthew Collier No No
217 Getting to know your proteins: A semi-automated protein purification platform for identifying and addressing protein specific issues.    Jack Doolan No Yes
218 A case study in accelerating SAR: Multiplexing LC-MS/MS based assays to reduce DMTA cycle times Siavash Kijani No No
219 Novel cryo-storage management software Cellseeker released for cell banking Niklas Rieck Yes Yes
220 Developing Image Analysis Workflows to Accelerate Drug Discovery Nina Vyas No Yes
221 Innovative and Physiologically relevant 3D Model for Immuno-Oncology Research Elspeth Ward No No
222 Using Benzo[d]thiazolo[3,2-a]imidazole and its Derivatives as Cell Fate Determinant Numb inducers for Triple Negative Breast Cancer Treatment Abdullah Al Dhfyan No Yes
223 Preparation and Evaluation of a Fluorescently labelled Liposome-A20FMDV2 Peptide Conjugate for αvβ6 Integrin Receptor-Targeting in Pancreatic Cancer Nermeen Ali No Yes
224 Usage of nivolumab platinum containing stat1 for suppression PD 1 genes in PD-1 /PD-L1 expressing cancer cells  Walid Atta No Yes
225 Application of microfluidic system for preparation of liposomal anti-tumour co-loaded with natural antioxidants for anti-tumour synergism and formulation stabilisation. Tia ATTIA No Yes
226 Integrated Drug Discovery – PD-1/PD-L1 Inhibitors Craig Avery Yes No
227 Nanobody-PROTACs: Method development towards using single-domain antibodies to target undruggable proteins for degradation Caroline Cope No Yes
228 Validating Targets for TPD using dTAG – a comprehensive workflow solution Joel Cresser-Brown Yes Yes
229 Testing Curcumin and Resveratrol as Novel Therapies for Endometrial Cancer in Patient Derived Explants  Gemma Donaldson No Yes
230 The role of inflammation in the development of BRAF-mutant colorectal cancer  Caleb Green No Yes
231 Standardized Target Carcinogenicity Assessment (TCA) Enables ICH S1B-based Regulatory Decisions   Frances Hall No No
232 Characterising the response of tumours to fractionated radiotherapy and immune checkpoint inhibitors Yin Ho Yes Yes
233 Investigating Inhibitors to CLIC1 for the treatment of Glioblastoma Multiforme Kay Osborn No No
234 Affimer reagents as novel genetic and cell biology tools to modulate the protein-protein interactions of Aurora kinase A Jack Roberts No Yes
235 High-throughput Spatial Biology analysis: Registration, Cell segmentation, Marker quantification and Statistical analysis with just a few clicks Lucas Schuetz No Yes
236 Accelerating drug discovery and therapeutic research using structural biology: small molecule and antibodies. Chitra Seewooruthun No Yes
237 Evaluating TRPML1 as a novel drug target for Triple Negative Breast Cancer (TNBC) Beth Tattersdill No Yes
238 Intrinsic expression of the cytokine receptor STX3 predicts response to α-PD-1 immune checkpoint inhibition in Non-Small Cell Lung Cancer Aimee Vaughan No Yes
239 Proteolysis-targeting chimera (PROTAC) technology for protein degradation of KAT2A in acute myeloid leukaemia – a novel therapeutic approach. Loren Waters No Yes
240 Improving the Antibacterial Activity of Fosfomycin and Colistin Antibiotics Using Thymoquinone in Liposomal Formulations Raghad Alzahrani No Yes
241 Bridging the Innovation Gap: Novel In Vivo Models for Late-Stage Retinal Diseases James Bojdo No Yes
242 Development and Validation of [3H]Cimbi-36 Binding in Mouse Frontal Cortex Including Affinity Constant Determination for Classical Psychedelics: Comparison to [3H]MDL100,907 Binding Michael Burnett Yes No
243 Psilocybin: the relationship between head twitch response, locomotor activity, 5-HT2A ex vivo receptor occupancy and plasma and brain levels of psilocin Albert Carter Yes Yes
244 Characterisation of a hiPSC-derived smooth muscle infection model for Trypanosoma cruzi drug screening Juliana Da Silva Pacheco No Yes
245 Investigation of cannabidiol as a potential therapeutic in Niemann-Pick disease Gareth Fenn No Yes
246 A new paradigm for the management of atrial fibrillation using budiodarone and wearable devices Christian Flynn No Yes
247 Structure determination of TRPC5 bound to the xanthine-based agonist AM237 Kasia Hammond No Yes
248 Effects of FDA approved drugs on the BMP and TGFβ signalling pathways in Pulmonary arterial hypertension (PAH)  Nura Mohammed No Yes
249 A 2.8 Å resolution crystal structure of Staphylococcus aureus  DNA gyrase in a cleavage complex with DNA and zoliflodacin suggests a mechanism for enhanced activity against quinolone-resistant bacteria Harry Morgan No Yes
250 Integrating basic science with clinical expertise to improve patient health. Anna Murray No No
251 Effect of Natural Compounds on BMP and TGFβ  Signalling Pathways in Pulmonary Arterial Hypertension Maria Osei No Yes
252 Spatially Resolved Whole Transcriptome Profiling of Fibroblastic Foci in Idiopathic Pulmonary Fibrosis. Robert Pedley No Yes
253 Exploring novel chemical space to identify small molecule mimetics of the RGD sequences of IGFBP-1 and IGFBP-2 to treat cardiometabolic disease.  Emily Rolfe No Yes
254 ProQuant™, a new precision proteomics platform Estere Seinkmane Yes Yes
255 Developing iPSC-derived models of neurodegenerative disease to test the therapeutic efficacy of Samsara’s autophagy modulators  Zahra Shather Yes Yes
256 Identification and Profiling of Biomarkers in Neurodegeneration Kerry Shea No No
257 Using FIDA to support Protein Science in Drug Discovery Duncan Smith Yes No
258 The effect of DNA methylation on CRISPR-induced toxicity Eve Stalker No Yes
259 Development of DUBTACs (Deubiquitinase Targeting Chimeras) for the Stabilisation of Protein Levels Amber Truepenny No Yes
260 Discovery of novel degraders for TPD applications utilising PROTEINi®-based functional screening Lucy Walker No Yes
261 A multi-scale approach to quantitatively evaluate the SMAD signaling pathway Julia Hillger Yes No
262 Biophysical and Biochemical Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders. Mauricio Martin Yes No







ABOUT US

ELRIG is a not-for-profit organisation serving the life science & drug discovery communities.

info@elrig.org